-
Product Insights
SSI Som Boulevard Villas
Equip yourself with the essential tools needed to make informed and profitable decisions with our SSI Som Boulevard Villas report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? ·Unleash the full story: Dive deep into the SSI Som...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SSI-361
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SSI-361 Drug Details SSI-361 is under development for the treatment of solid tumors including...
-
Product Insights
Mycobacterium Tuberculosis Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Traditional diagnosis of Mycobacterial infections depends upon smear positivity in sputum samples, culture, and chest radiography. For rapid diagnosis, polymerase chain reaction (PCR), immune-based assays such as enzyme-linked immunosorbent assay (ELISA), skin patch test, and rapid culture systems are performed. The Mycobacterium tuberculosis tests pipeline market research report provides comprehensive information about the Mycobacterium tuberculosis tests pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Thematic Analysis
Microbiome-Targeted Therapeutics in Immunology
Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.
-
Sector Analysis
EpiCast Report: Healthcare-Associated Gram-Negative Infections – Epidemiology Forecast to 2026
Healthcare-associated infections (HAIs) are a major threat to patient safety. HAIs occur in hospitalized patients, and are not present at the time of admission. The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia (HAP)/ventilator-associated pneumonia (VAP), and surgical site infection (SSI). Infections caused by Gram-negative bacteria are of particular public health concern,...
-
Sector Analysis
PharmaPoint: Healthcare-Associated Gram-Negative Infections – Global Drug Forecast and Market Analysis to 2026
Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories:...